<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989963</url>
  </required_header>
  <id_info>
    <org_study_id>BPS-MR-PAH-203</org_study_id>
    <nct_id>NCT00989963</nct_id>
  </id_info>
  <brief_title>Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)</brief_title>
  <official_title>A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Biotechnology PBC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Biotechnology PBC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, international, multicenter, double-blind, three-group, dose-response study&#xD;
      to assess the safety and efficacy of BPS-MR in patients with PAH. Eligible patients will have&#xD;
      been previously diagnosed with PAH and will be on a stable course of an ERA and/or PDE-5&#xD;
      inhibitor for at least 60 days prior to Baseline.&#xD;
&#xD;
      Patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio and will be&#xD;
      stratified by PAH background therapy (Endothelium Receptor Antagonist (ERA),&#xD;
      Phosphodiesterase-5 (PDE-5), and both). The treatment groups consist of one Maximum Tolerated&#xD;
      Dose (MTD) and two Fixed Dose (FD) groups. Following randomization, patients will begin&#xD;
      taking active drug (60µg) orally twice daily. Patients will visit their investigational site&#xD;
      at Week 6 and Week 12 for study evaluations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week, international, multicenter, double-blind, three-group, dose-response study&#xD;
      to assess the safety and efficacy of BPS-MR in patients with PAH. Eligible patients will have&#xD;
      been previously diagnosed with PAH and will be on a stable course of an ERA and/or PDE-5&#xD;
      inhibitor for at least 60 days prior to Baseline.&#xD;
&#xD;
      A total of approximately 36 patients will be randomized to 1 of 3 treatment groups (12 per&#xD;
      group) in a 1:1:1 ratio and will be stratified by PAH background therapy (ERA, PDE-5, and&#xD;
      both). The treatment groups consist of one MTD and two FD groups. Following randomization,&#xD;
      patients will begin taking active drug (60µg) orally twice daily. Patients will visit their&#xD;
      investigational site at Week 6 and Week 12 for study evaluations. Between visits, clinical&#xD;
      site personnel will contact patients by phone each week to assess tolerability, provide&#xD;
      instructions for a change in dosage, record changes in concomitant medications, and record&#xD;
      adverse events. Patients who complete the study will be offered the opportunity to continue&#xD;
      taking study medication in a separate open-label continuation protocol. Patients who withdraw&#xD;
      early from the study or who otherwise do not elect to enroll into the open-label continuation&#xD;
      protocol will be down-titrated off of BPS-MR at the discretion of the Investigator, at a&#xD;
      maximum decrement not to exceed one tablet (60µg) b.i.d. per day and a minimum decrement of&#xD;
      one tablet (60µg) b.i.d. per week.&#xD;
&#xD;
      Patients in the iMTD treatment group will dose escalate weekly by 60µg b.i.d. until they&#xD;
      reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them&#xD;
      to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion,&#xD;
      further attempts at dose escalation may be made.&#xD;
&#xD;
      The FD treatment groups will consist of a low dose group receiving 60µg b.i.d. and a high&#xD;
      dose group receiving 240µg b.i.d. Patients in the high dose group will dose escalate weekly&#xD;
      by 60µg b.i.d. until they reach the fixed dose of 240µg b.i.d. Once patients in these&#xD;
      treatment groups have reached their assigned maximum dose of active drug, weekly increases in&#xD;
      the number of placebo tablets administered will continue in order to maintain the blind.&#xD;
&#xD;
      Patients will be requested to maintain a daily diary of symptoms and study drug&#xD;
      administration for evaluation by clinical site personnel. Also, patients will be given the&#xD;
      option to contribute blood for pharmacokinetic assessment of BPS/BPS-314d plasma&#xD;
      concentrations at the Week 12 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2010</start_date>
  <completion_date type="Actual">September 13, 2011</completion_date>
  <primary_completion_date type="Actual">September 13, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pulmonary Vascular Resistance at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The change in Pulmonary Vascular Resistance (PVR) was evaluated from Baseline to Week 12. PVR is expressed in Wood Units or millimeters of Mercury per Liter per minute (mmHG/L/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cardiac Output (CO) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The change in Cardiac Output was evaluated from Baseline to Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulmonary Arterial Pressure at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The change in mean Pulmonary Arterial Pressure (mPAP) was evaluated from Baseline to Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Six Minute Walk Distance From Baseline to Week 6 and Week 12</measure>
    <time_frame>Baseline, Week 6 and 12</time_frame>
    <description>Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called &quot;stop&quot; while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each World Health Organization (WHO) Functional Class for Pulmonary Arterial Hypertension (PAH) at Week 6 and 12</measure>
    <time_frame>Week 6 and Week 12</time_frame>
    <description>WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Post-baseline Clinically Significant Laboratory Value</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Post-baseline clinically significant values, as defined by the Investigator, for hematology, serum chemistry, coagulation and urinalysis parameters were summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Newly Occurring Clinically Significant ECG Abnormalities</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Clinically significant ECG abnormalities at Baseline only are excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg Dyspnea Score From Baseline to Week 6 and Week 12</measure>
    <time_frame>Baseline, Week 6 and 12</time_frame>
    <description>The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-Terminal ProB-type Natriuretic Peptide Level at Week 6 and Week 12</measure>
    <time_frame>Week 6 and Week 12</time_frame>
    <description>NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary arterial hypertension.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Maximum Tolerated Dose (MTD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Fixed Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The low dose group will receive 60µg twice a day(b.i.d.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Fixed Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost Sodium Modified Release</intervention_name>
    <description>60µg Tablets, twice a day for 12 weeks</description>
    <arm_group_label>High Fixed Dose</arm_group_label>
    <arm_group_label>Low Fixed Dose</arm_group_label>
    <arm_group_label>Maximum Tolerated Dose (MTD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. IRB approved written informed consent has been obtained.&#xD;
&#xD;
          2. Male or female, age 18 to 75 years (inclusive).&#xD;
&#xD;
          3. Established diagnosis of pulmonary arterial hypertension that is either idiopathic or&#xD;
             familial PAH, collagen vascular disease associated PAH, PAH induced by anorexigens, or&#xD;
             PAH associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥5&#xD;
             years).&#xD;
&#xD;
          4. Clinically stable PAH as determined by the Investigator.&#xD;
&#xD;
          5. Able to walk unassisted.&#xD;
&#xD;
          6. Has a complete, unencouraged 6MWT distance of 150 to 450 meters (inclusive) at&#xD;
             Screening.&#xD;
&#xD;
          7. Previous (at any time) right heart cardiac catheterization with findings consistent&#xD;
             with PAH, specifically mean Pulmonary Arterial Pressure (PAPm) ≥25 mmHg (at rest),&#xD;
             Pulmonary Capillary Wedge Pressure (PCWP) (or left ventricular end diastolic pressure)&#xD;
             ≤15 mmHg, and Pulmonary Vascular Resistance (PVR) &gt;3 mmHg/L/min.&#xD;
&#xD;
          8. Previous (at any time) chest radiograph consistent with the diagnosis of PAH.&#xD;
&#xD;
          9. Has been on a stable course of an ERA or/and PDE-5 inhibitor for a minimum of 60 days&#xD;
             prior to Baseline.&#xD;
&#xD;
         10. Women of child-bearing potential (defined as less than 1 year post-menopausal or not&#xD;
             surgically sterile) must be using an acceptable method of birth control or practicing&#xD;
             abstinence. If sexually active, female patients must use a double barrier method of&#xD;
             birth control, such as a condom and spermicidal. Patient must have a negative&#xD;
             pregnancy test at the Screening and Baseline visits.&#xD;
&#xD;
         11. Willing and able to comply with study requirements and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has pulmonary venous hypertension, pulmonary veno-occlusive disease, pulmonary&#xD;
             capillary hemangiomatosis, or chronic thromboembolic pulmonary hypertension.&#xD;
&#xD;
          2. Has a history of interstitial lung disease, unless:&#xD;
&#xD;
               -  Pulmonary Function Testing conducted within 6 months of the Baseline visit&#xD;
                  demonstrates a Total Lung Capacity ≥ 70 % of predicted.&#xD;
&#xD;
          3. Has a history of obstructive lung disease, unless:&#xD;
&#xD;
               -  Pulmonary Function Testing conducted within 6 months of the Baseline visit&#xD;
                  demonstrates a forced expiratory volume in 1 second/forced vital capacity&#xD;
                  (FEV1/FVC) ratio of ≥ 50%.&#xD;
&#xD;
          4. Is pregnant and/or lactating.&#xD;
&#xD;
          5. Changed or discontinued any PAH medication within 60 days prior to the Baseline visit&#xD;
             including, but not limited to, an ERA, PDE-5 inhibitor, or calcium channel blocker&#xD;
             (with the exception of anticoagulants).&#xD;
&#xD;
          6. Has an ongoing hemorrhagic condition (e.g. upper digestive tract hemorrhage,&#xD;
             hemoptysis, etc), or has a pre-existing condition that, in the Investigator's judgment&#xD;
             may increase the risk for developing hemorrhage during the study (e.g. hemophilia).&#xD;
             Transient hemorrhage (e.g. epistaxis, normal menstrual bleeding, gingival bleeding,&#xD;
             hemorrhoidal hemorrhage, etc.) will not preclude enrollment.&#xD;
&#xD;
          7. Has donated blood or plasma, or has lost a volume of blood &gt;450mL within 6-weeks of&#xD;
             the Baseline visit.&#xD;
&#xD;
          8. Has received any investigational medication, device or therapy within 30 days prior to&#xD;
             the Baseline visit or is scheduled to receive another investigational drug, device or&#xD;
             therapy during the course of the study.&#xD;
&#xD;
          9. Has received any prostanoid therapy at any time.&#xD;
&#xD;
         10. Has any preexisting disease known to cause pulmonary hypertension other than collagen&#xD;
             vascular disease.&#xD;
&#xD;
         11. Has any musculoskeletal disease or any other disease that would limit ambulation.&#xD;
&#xD;
         12. Has any form of unrepaired or recently repaired (&lt; 5 years) congenital&#xD;
             systemic-to-pulmonary shunt other than patent foramen ovale.&#xD;
&#xD;
         13. History of pulmonary embolism or deep venous thrombosis.&#xD;
&#xD;
         14. History of ischemic heart disease, including previous myocardial infarction, or&#xD;
             symptomatic coronary artery disease, or history of left sided myocardial disease as&#xD;
             evidenced by a mean PCWP (or a left ventricular end diastolic pressure) &gt; 15 mmHg or&#xD;
             left ventricular ejection fraction &lt; 40% as assessed by either multigated angiogram,&#xD;
             angiography or echocardiography, or left ventricular shortening fraction &lt; 22% as&#xD;
             assessed by echocardiography. Note that patients in whom abnormal left ventricular&#xD;
             function is attributed entirely to impaired left ventricular filling due to the&#xD;
             effects of right ventricular overload (i.e. right ventricular hypertrophy and/or&#xD;
             dilatation) will not be excluded.&#xD;
&#xD;
         15. Presence of atrial fibrillation (determined from 12-lead ECG at Screening).&#xD;
&#xD;
         16. Any other clinically significant illness that, in the opinion of the Investigator,&#xD;
             might put the patient at risk of harm during the study or might adversely affect the&#xD;
             interpretation of the study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Heart Hospital</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles</name>
      <address>
        <city>Bruxellas</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Teaching Hospital</name>
      <address>
        <city>Praha</city>
        <zip>2, 128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat zu Koln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abt. Innere Medizin III, Medizinische Universitatsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Leipzig Abteilung Pulmologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital Ltd.</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Urgenta pentru Boli</name>
      <address>
        <city>Bucuresti</city>
        <zip>022322</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Pneumologie</name>
      <address>
        <city>Bucuresti</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul de Boli Cardiovasculare</name>
      <address>
        <city>Lasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <results_first_submitted>July 20, 2020</results_first_submitted>
  <results_first_submitted_qc>September 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2020</results_first_posted>
  <disposition_first_submitted>April 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2013</disposition_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Fixed Dose Group (60 ug)</title>
          <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
        </group>
        <group group_id="P2">
          <title>High Fixed Dose (FD) Group (240 ug)</title>
          <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
        </group>
        <group group_id="P3">
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="13">1 participant randomized to MTD received FD 60 ug; was included in FD 60 ug arm for this population</participants>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11">1 participant randomized to MTD received FD 60 ug; was included in FD 60 ug arm for this population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="12">1 participant randomized to MTD received FD 60 ug; was included in FD 60 ug arm for this population</participants>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10">1 participant randomized to MTD received FD 60 ug; was included in FD 60 ug arm for this population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all participants who were randomized in the study (per intended treatment assignment).</population>
      <group_list>
        <group group_id="B1">
          <title>Low Fixed Dose Group (60 ug)</title>
          <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
        </group>
        <group group_id="B2">
          <title>High Fixed Dose Group (240 ug)</title>
          <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
        </group>
        <group group_id="B3">
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="14.19"/>
                    <measurement group_id="B2" value="45.1" spread="15.2"/>
                    <measurement group_id="B3" value="51.1" spread="14.71"/>
                    <measurement group_id="B4" value="47.4" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonary Vascular Resistance (PVR)</title>
          <description>Pulmonary Vascular Resistance the difference between is the mean pulmonary arterial pressure and the left atrial filling pressure divided by the cardiac output.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>Wood Units (mmHg/L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.74" spread="5.35"/>
                    <measurement group_id="B2" value="9.39" spread="4.05"/>
                    <measurement group_id="B3" value="10.19" spread="5.61"/>
                    <measurement group_id="B4" value="9.76" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Output (CO)</title>
          <description>Cardiac Output is the effective volume of blood expelled by either ventricle of the heart per unit of time (generally per minute); it usually refers to left ventricle output. It is equal to the stroke volume multiplied by the heart rate.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>Liters per minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.44" spread="1.12"/>
                    <measurement group_id="B2" value="5.53" spread="1.79"/>
                    <measurement group_id="B3" value="4.52" spread="1.20"/>
                    <measurement group_id="B4" value="4.83" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Pulmonary Arterial Pressure (mPAP)</title>
          <description>Mean Pulmonary Arterial Pressure (mPAP) is a directly measured hemodynamic parameter. mPAP is recorded during right heart catheterization.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>Millimeters of Mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.58" spread="18.72"/>
                    <measurement group_id="B2" value="57.91" spread="19.03"/>
                    <measurement group_id="B3" value="52.40" spread="15.54"/>
                    <measurement group_id="B4" value="53.21" spread="17.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Six Minute Walk Distance</title>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>meters (m)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362.92" spread="51.01"/>
                    <measurement group_id="B2" value="388.73" spread="74.21"/>
                    <measurement group_id="B3" value="327.70" spread="94.48"/>
                    <measurement group_id="B4" value="360.85" spread="75.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Borg Dyspnea Score</title>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="10"/>
                    <count group_id="B4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.71" spread="1.48"/>
                    <measurement group_id="B2" value="3.36" spread="2.34"/>
                    <measurement group_id="B3" value="3.10" spread="2.27"/>
                    <measurement group_id="B4" value="3.05" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulmonary Vascular Resistance at Week 12</title>
        <description>The change in Pulmonary Vascular Resistance (PVR) was evaluated from Baseline to Week 12. PVR is expressed in Wood Units or millimeters of Mercury per Liter per minute (mmHG/L/min)</description>
        <time_frame>Week 12</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Vascular Resistance at Week 12</title>
          <description>The change in Pulmonary Vascular Resistance (PVR) was evaluated from Baseline to Week 12. PVR is expressed in Wood Units or millimeters of Mercury per Liter per minute (mmHG/L/min)</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>Wood Units (mmHg/L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="3.08"/>
                    <measurement group_id="O2" value="0.00" spread="1.57"/>
                    <measurement group_id="O3" value="0.13" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cardiac Output (CO) at Week 12</title>
        <description>The change in Cardiac Output was evaluated from Baseline to Week 12.</description>
        <time_frame>Week 12</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardiac Output (CO) at Week 12</title>
          <description>The change in Cardiac Output was evaluated from Baseline to Week 12.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>Liters per minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="1.17"/>
                    <measurement group_id="O2" value="0.07" spread="0.84"/>
                    <measurement group_id="O3" value="0.35" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulmonary Arterial Pressure at Week 12</title>
        <description>The change in mean Pulmonary Arterial Pressure (mPAP) was evaluated from Baseline to Week 12.</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulmonary Arterial Pressure at Week 12</title>
          <description>The change in mean Pulmonary Arterial Pressure (mPAP) was evaluated from Baseline to Week 12.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="5.76"/>
                    <measurement group_id="O2" value="-1.45" spread="11.96"/>
                    <measurement group_id="O3" value="4.10" spread="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Six Minute Walk Distance From Baseline to Week 6 and Week 12</title>
        <description>Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called &quot;stop&quot; while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted.</description>
        <time_frame>Baseline, Week 6 and 12</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Six Minute Walk Distance From Baseline to Week 6 and Week 12</title>
          <description>Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called &quot;stop&quot; while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population).</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 Peak</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="112.63"/>
                    <measurement group_id="O2" value="29.91" spread="46.83"/>
                    <measurement group_id="O3" value="39.90" spread="47.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Peak</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.82" spread="70.53"/>
                    <measurement group_id="O2" value="42.18" spread="83.08"/>
                    <measurement group_id="O3" value="47.10" spread="48.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 Trough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.00" spread="50.74"/>
                    <measurement group_id="O2" value="47.67" spread="92.20"/>
                    <measurement group_id="O3" value="11.67" spread="72.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each World Health Organization (WHO) Functional Class for Pulmonary Arterial Hypertension (PAH) at Week 6 and 12</title>
        <description>WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest).</description>
        <time_frame>Week 6 and Week 12</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population). Here, number analyzed signifies number of participants evaluable at specified time points only.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each World Health Organization (WHO) Functional Class for Pulmonary Arterial Hypertension (PAH) at Week 6 and 12</title>
          <description>WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest).</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol Population). Here, number analyzed signifies number of participants evaluable at specified time points only.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6: Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Class I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Class IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Post-baseline Clinically Significant Laboratory Value</title>
        <description>Post-baseline clinically significant values, as defined by the Investigator, for hematology, serum chemistry, coagulation and urinalysis parameters were summarized.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>Randomized participants (per actual treatment received) who received ≥1 dose of study drug (Safety Population). Overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Post-baseline Clinically Significant Laboratory Value</title>
          <description>Post-baseline clinically significant values, as defined by the Investigator, for hematology, serum chemistry, coagulation and urinalysis parameters were summarized.</description>
          <population>Randomized participants (per actual treatment received) who received ≥1 dose of study drug (Safety Population). Overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Newly Occurring Clinically Significant ECG Abnormalities</title>
        <description>Clinically significant ECG abnormalities at Baseline only are excluded.</description>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Randomized participants (per actual treatment received) who received ≥1 dose of study drug (Safety Population). Overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Newly Occurring Clinically Significant ECG Abnormalities</title>
          <description>Clinically significant ECG abnormalities at Baseline only are excluded.</description>
          <population>Randomized participants (per actual treatment received) who received ≥1 dose of study drug (Safety Population). Overall number of participants analyzed signifies those who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Atrial Abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Pulmonary Disease Pattern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low QRS Voltage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Specific ST-T Changes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Borg Dyspnea Score From Baseline to Week 6 and Week 12</title>
        <description>The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted.</description>
        <time_frame>Baseline, Week 6 and 12</time_frame>
        <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol [PP] Population).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Borg Dyspnea Score From Baseline to Week 6 and Week 12</title>
          <description>The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted.</description>
          <population>Randomized participants (actual treatment received) who had completed the study and had received the required protocol processing for the study, i.e., no major protocol deviations (Per-Protocol [PP] Population).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="1.29"/>
                    <measurement group_id="O2" value="0.68" spread="1.65"/>
                    <measurement group_id="O3" value="0.80" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 at peak</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.81"/>
                    <measurement group_id="O2" value="0.64" spread="2.16"/>
                    <measurement group_id="O3" value="0.40" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 at trough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.83"/>
                    <measurement group_id="O2" value="1.11" spread="0.78"/>
                    <measurement group_id="O3" value="0.67" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-Terminal ProB-type Natriuretic Peptide Level at Week 6 and Week 12</title>
        <description>NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary arterial hypertension.</description>
        <time_frame>Week 6 and Week 12</time_frame>
        <population>Randomized participants (actual treatment received) who completed the study and received required protocol processing, ie, no major protocol deviations (PP Population). Overall number of participants analyzed signifies those who were evaluable for the outcome measure; number analyzed signifies those who were evaluable at specified timepoint only.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Fixed Dose Group (60 ug)</title>
            <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
          </group>
          <group group_id="O2">
            <title>High Fixed Dose Group (240 ug)</title>
            <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
          </group>
          <group group_id="O3">
            <title>Maximum Tolerated Dose (MTD)</title>
            <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
          </group>
        </group_list>
        <measure>
          <title>N-Terminal ProB-type Natriuretic Peptide Level at Week 6 and Week 12</title>
          <description>NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary arterial hypertension.</description>
          <population>Randomized participants (actual treatment received) who completed the study and received required protocol processing, ie, no major protocol deviations (PP Population). Overall number of participants analyzed signifies those who were evaluable for the outcome measure; number analyzed signifies those who were evaluable at specified timepoint only.</population>
          <units>nanograms per Liter (ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="1.28"/>
                    <measurement group_id="O2" value="5.82" spread="0.72"/>
                    <measurement group_id="O3" value="6.83" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.33" spread="1.41"/>
                    <measurement group_id="O2" value="6.06" spread="1.08"/>
                    <measurement group_id="O3" value="6.85" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 30 days after last dose of study drug (up to Week 12).</time_frame>
      <desc>Randomized participants (per actual treatment received) who received ≥1 dose of study drug (Safety Population).</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Fixed Dose Group (60 ug)</title>
          <description>Participants in the low dose group received 60 microgram of Beraprost sodium modified release tablets, orally twice daily up to maximum duration of Week 12.</description>
        </group>
        <group group_id="E2">
          <title>High Fixed Dose Group (240 ug)</title>
          <description>Participants in the high dose group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 240 microgram twice daily up to a maximum duration of Week 12</description>
        </group>
        <group group_id="E3">
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Participants in this group received starting dose of 60 microgram of Beraprost sodium modified release tablets twice daily which was escalated until they reached the fixed maximum dose of 600 microgram twice daily up to a maximum duration of Week 12 or they reached an intolerable dose which required them to down-titrate by 60 microgram twice daily in these instances and at the Investigator's discretion, further attempts at dose escalation may have been made.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myodesopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Brain natriuretic peptide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>N-terminal prohormone brain natriuretic peptide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vein disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lung Biotechnology PBC Study Director</name_or_title>
      <organization>Lung Biotechnology PBC</organization>
      <email>info@lungbiotechnology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

